Jung Young-Hwan, Kim Yeo Ok, Kang Koon Mook, Lee Hyung Gon, Son Borum, Han Xuehao, Oh Eunseok, Kim Siwon, Seo Seon Hee, Park Jong-Hyun, Park Ki Duk, Kim Woong Mo, Yoon Myung Ha, Kim Yong-Chul
School of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju 61005, Korea.
Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School, Gwangju 61469, Korea.
Pharmaceuticals (Basel). 2022 Mar 27;15(4):407. doi: 10.3390/ph15040407.
Neuropathic pain is a chronic and sometimes intractable condition caused by lesions or diseases of the somatosensory nervous system. Many drugs are available but unfortunately do not provide satisfactory effects in patients, producing limited analgesia and undesirable side effects. Thus, there is an urgent need to develop new pharmaceutical agents to treat neuropathic pain. To date, highly specific agents that modulate a single target, such as receptors or ion channels, never progress to the clinic, which may reflect the diverse etiologies of neuropathic pain seen in the human patient population. Therefore, the development of multifunctional compounds exhibiting two or more pharmacological activities is an attractive strategy for addressing unmet medical needs for the treatment of neuropathic pain. To develop novel multifunctional compounds, key pharmacophores of currently used clinical pain drugs, including pregabalin, fluoxetine and serotonin analogs, were hybridized to the side chain of tianeptine, which has been used as an antidepressant. The biological activities of the hybrid analogs were evaluated at the human transporters of neurotransmitters, including serotonin (hSERT), norepinephrine (hNET) and dopamine (hDAT), as well as mu (μ) and kappa (κ) opioid receptors. The most advanced hybrid of these multifunctional compounds, , exhibited multiple transporter inhibitory activities for the uptake of neurotransmitters with IC values of 70 nM, 154 nM and 2.01 μM at hSERT, hNET and hDAT, respectively. Additionally, compound showed partial agonism (EC = 384 nM) at the μ-opioid receptor with no influence at the κ-opioid receptor. In in vivo pain animal experiments, the multifunctional compound showed significantly reduced allodynia in a spinal nerve ligation (SNL) model by intrathecal administration, indicating that multitargeted strategies in single therapy could considerably benefit patients with multifactorial diseases, such as pain.
神经性疼痛是一种由躯体感觉神经系统的损伤或疾病引起的慢性、有时甚至难以治疗的病症。虽然有许多药物可供使用,但遗憾的是,这些药物对患者并未产生令人满意的效果,镇痛效果有限且会产生不良副作用。因此,迫切需要开发新的药物来治疗神经性疼痛。迄今为止,高度特异性的、调节单一靶点(如受体或离子通道)的药物从未进入临床阶段,这可能反映了人类患者群体中神经性疼痛病因的多样性。因此,开发具有两种或更多药理活性的多功能化合物是满足神经性疼痛治疗中未满足医疗需求的一种有吸引力的策略。为了开发新型多功能化合物,将目前用于临床疼痛治疗的药物(包括普瑞巴林、氟西汀和血清素类似物)的关键药效基团与已用作抗抑郁药的噻奈普汀的侧链进行杂交。在神经递质的人类转运体上评估了杂交类似物的生物活性,这些转运体包括血清素(hSERT)、去甲肾上腺素(hNET)和多巴胺(hDAT),以及μ和κ阿片受体。这些多功能化合物中最先进的杂交体,分别在hSERT、hNET和hDAT上对神经递质的摄取表现出多种转运体抑制活性,其IC值分别为70 nM、154 nM和2.01 μM。此外,化合物在μ阿片受体上表现出部分激动作用(EC = 384 nM),对κ阿片受体无影响。在体内疼痛动物实验中,多功能化合物通过鞘内给药在脊髓神经结扎(SNL)模型中显示出明显减轻的异常性疼痛,这表明单一疗法中的多靶点策略可以使患有多因素疾病(如疼痛)的患者受益匪浅。